Literature DB >> 15860716

Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors.

D S Hui1, G M Joynt, K T Wong, C D Gomersall, T S Li, G Antonio, F W Ko, M C Chan, D P Chan, M W Tong, T H Rainer, A T Ahuja, C S Cockram, J J Y Sung.   

Abstract

OBJECTIVE: To examine the impact of severe acute respiratory syndrome (SARS) on pulmonary function, exercise capacity, and health-related quality of life (HRQoL) among survivors.
METHODS: 110 survivors with confirmed SARS were evaluated at the Prince of Wales Hospital, HK at the end of 3 and 6 months after symptom onset. The assessment included lung volumes (TLC, VC, RV, FRC), spirometry (FVC, FEV1), carbon monoxide transfer factor (TLCO adjusted for haemoglobin), inspiratory and expiratory respiratory muscle strength (Pimax and Pemax), 6 minute walk distance (6MWD), chest radiographs, and HRQoL by SF-36 questionnaire.
RESULTS: There were 44 men and 66 women with a mean (SD) age of 35.6 (9.8) years and body mass index of 23.1 (4.8) kg/m2. Seventy (64%) were healthcare workers. At 6 months 33 subjects (30%) had abnormal chest radiographs; four (3.6%), eight (7.4%), and 17 (15.5%) patients had FVC, TLC, and TLCO below 80% of predicted values; and 15 (13.9%) and 24 (22.2%) had Pimax and Pemax values below 80 cm H2O, respectively. The 6MWD increased from a mean (SD) of 464 (83) m at 3 months to 502 (95) m (95% CI 22 to 54 m, p<0.001), but the results were lower than normal controls in the same age groups. There was impairment of HRQoL at 6 months. Patients who required ICU admission (n = 31) had significantly lower FVC, TLC, and TLCO than those who did not.
CONCLUSION: The exercise capacity and health status of SARS survivors was considerably lower than that of a normal population at 6 months. Significant impairment in surface area for gas exchange was noted in 15.5% of survivors. The functional disability appears out of proportion to the degree of lung function impairment and may be related to additional factors such as muscle deconditioning and steroid myopathy.

Entities:  

Mesh:

Year:  2005        PMID: 15860716      PMCID: PMC1758905          DOI: 10.1136/thx.2004.030205

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  51 in total

Review 1.  Clinical exercise testing.

Authors:  I M Weisman; R J Zeballos
Journal:  Clin Chest Med       Date:  2001-12       Impact factor: 2.878

2.  Long-term assessment of lung function in survivors of severe ARDS.

Authors:  Thomas A Neff; Reto Stocker; Hans-Rudolf Frey; Sonja Stein; Erich W Russi
Journal:  Chest       Date:  2003-03       Impact factor: 9.410

Review 3.  Myopathy in critically ill patients.

Authors:  E Hund
Journal:  Crit Care Med       Date:  1999-11       Impact factor: 7.598

4.  Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels.

Authors:  L Larsson; X Li; L Edström; L I Eriksson; H Zackrisson; C Argentini; S Schiaffino
Journal:  Crit Care Med       Date:  2000-01       Impact factor: 7.598

5.  Pulmonary function and health-related quality of life in a sample of long-term survivors of the acute respiratory distress syndrome.

Authors:  G Schelling; C Stoll; C Vogelmeier; T Hummel; J Behr; H P Kapfhammer; H B Rothenhäusler; M Haller; K Durst; T Krauseneck; J Briegel
Journal:  Intensive Care Med       Date:  2000-09       Impact factor: 17.440

6.  One-year outcomes in survivors of the acute respiratory distress syndrome.

Authors:  Margaret S Herridge; Angela M Cheung; Catherine M Tansey; Andrea Matte-Martyn; Natalia Diaz-Granados; Fatma Al-Saidi; Andrew B Cooper; Cameron B Guest; C David Mazer; Sangeeta Mehta; Thomas E Stewart; Aiala Barr; Deborah Cook; Arthur S Slutsky
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

Review 7.  Virus-induced airway hyperresponsiveness in man.

Authors:  P J Sterk
Journal:  Eur Respir J       Date:  1993-06       Impact factor: 16.671

8.  Pulmonary function and health-related quality of life in survivors of acute respiratory distress syndrome.

Authors:  James Orme; Joshua S Romney; Ramona O Hopkins; Donna Pope; Karen J Chan; George Thomsen; Robert O Crapo; Lindell K Weaver
Journal:  Am J Respir Crit Care Med       Date:  2002-12-18       Impact factor: 21.405

9.  Steroid-induced myopathy in the ICU.

Authors:  Bryan W Polsonetti; Saju D Joy; Luis F Laos
Journal:  Ann Pharmacother       Date:  2002-11       Impact factor: 3.154

Review 10.  Weakness of respiratory and skeletal muscles after a short course of steroids in patients with acute lung rejection.

Authors:  S Nava; C Fracchia; G Callegari; N Ambrosino; N Barbarito; G Felicetti
Journal:  Eur Respir J       Date:  2002-08       Impact factor: 16.671

View more
  150 in total

1.  Neuromusculoskeletal disorders following SARS: a case series.

Authors:  Brynne Stainsby; Scott Howitt; Jason Porr
Journal:  J Can Chiropr Assoc       Date:  2011-03

2.  Longer term follow up of aerobic capacity in children affected by severe acute respiratory syndrome (SARS).

Authors:  C C W Yu; A M Li; R C H So; A McManus; P C Ng; W Chu; D Chan; F Cheng; W K Chiu; C W Leung; Y S Yau; K W Mo; E M C Wong; A Y K Cheung; T F Leung; R Y T Sung; T F Fok
Journal:  Thorax       Date:  2006-01-31       Impact factor: 9.139

3.  Respiratory muscle strength predicts decline in mobility in older persons.

Authors:  A S Buchman; P A Boyle; R S Wilson; S Leurgans; R C Shah; D A Bennett
Journal:  Neuroepidemiology       Date:  2008-09-11       Impact factor: 3.282

Review 4.  Core outcomes sets for studies evaluating critical illness and patient recovery.

Authors:  Victor D Dinglas; Sai P S Cherukuri; Dale M Needham
Journal:  Curr Opin Crit Care       Date:  2020-10       Impact factor: 3.687

Review 5.  Participant Retention in Follow-Up Studies of Acute Respiratory Failure Survivors.

Authors:  Krishidhar Nunna; Awsse Al-Ani; Roozbeh Nikooie; Lisa Aronson Friedman; Vaishnavi Raman; Zerka Wadood; Sumana Vasishta; Elizabeth Colantuoni; Dale M Needham; Victor D Dinglas
Journal:  Respir Care       Date:  2020-03-31       Impact factor: 2.258

Review 6.  Post-acute COVID-19 syndrome.

Authors:  Ani Nalbandian; Kartik Sehgal; Aakriti Gupta; Mahesh V Madhavan; Claire McGroder; Jacob S Stevens; Joshua R Cook; Anna S Nordvig; Daniel Shalev; Tejasav S Sehrawat; Neha Ahluwalia; Behnood Bikdeli; Donald Dietz; Caroline Der-Nigoghossian; Nadia Liyanage-Don; Gregg F Rosner; Elana J Bernstein; Sumit Mohan; Akinpelumi A Beckley; David S Seres; Toni K Choueiri; Nir Uriel; John C Ausiello; Domenico Accili; Daniel E Freedberg; Matthew Baldwin; Allan Schwartz; Daniel Brodie; Christine Kim Garcia; Mitchell S V Elkind; Jean M Connors; John P Bilezikian; Donald W Landry; Elaine Y Wan
Journal:  Nat Med       Date:  2021-03-22       Impact factor: 53.440

7.  Medium-Term Outcomes in Severely to Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Authors:  Nandan Gautam; Shyam Madathil; Natascia Tahani; Shaun Bolton; Dhruv Parekh; James Stockley; Shraddha Goyal; Hannah Qureshi; Sadhika Yasmin; Brendan G Cooper; Jennifer Short; Tarekegn Geberhiwot
Journal:  Clin Infect Dis       Date:  2022-01-29       Impact factor: 9.079

8.  Evaluation of the relationship between laboratory parameters and pulmonary function tests in COVID-19 patients.

Authors:  Buğra Kerget; Alperen Aksakal; Ferhan Kerget
Journal:  Int J Clin Pract       Date:  2021-04-27       Impact factor: 3.149

9.  COVID-19: persistence of symptoms and lung alterations after 3-6 months from hospital discharge.

Authors:  Alberto Fortini; Arianna Torrigiani; Serena Sbaragli; Aldo Lo Forte; Andrea Crociani; Paolo Cecchini; Giulia Innocenti Bruni; Antonio Faraone
Journal:  Infection       Date:  2021-06-06       Impact factor: 7.455

10.  Alterations in Respiratory Function Test Three Months after Hospitalisation for COVID-19 Pneumonia: Value of Determining Nitric Oxide Diffusion.

Authors:  Marta Núñez-Fernández; Cristina Ramos-Hernández; Francisco García-Río; María Torres-Durán; Andrés Nodar-Germiñas; Amara Tilve-Gómez; Paula Rodríguez-Fernández; Diana Valverde-Pérez; Alberto Ruano-Raviña; Alberto Fernández-Villar
Journal:  J Clin Med       Date:  2021-05-14       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.